This screening revealed statistically significant enhanced NKX2-1 activity in 11 (5%) DLBCL patients (Fig. 1D), supporting the relevance of this oncogenic homeobox gene expression in this malignancy. This evidence concerns the gene NKX2-1 and diffuse large B-cell lymphoma.